Neil Carragher
Professor of Drug Discovery and Director of Translation, University of Edinburgh

- Cancer Research UK Edinburgh Centre
- MRC Institute of Genetics & Cancer
Contact details
- Tel: +44 (0)131 651 8690
- Director of the Edinburgh Cancer Discovery Unit and Edinburgh Phenotypic Assay Centre
- Institute of Genetics and Cancer
- Edinburgh Drug Discovery
Address
- Street
-
Cancer Research UK Edinburgh Centre
MRC Institute of Genetics & Cancer
The University of Edinburgh
Western General Hospital
Crewe Road South - City
- Edinburgh
- Post code
- EH4 2XR
- Street
-
PA : jan.irvine@ed.ac.uk
- City
- Post code
Background
Professor Neil Carragher graduated from the University of Aberdeen, Scotland UK in 1992 with a B.Sc Honours degree in the subject of “Cell and Immunobiology”. He then took up a position within industry at the Yamanouchi Research Institute, Oxford, England UK where he also gained his PhD. He then held consecutive postdoctoral positions within the Department of Pathology, University of Washington, Seattle, USA and at the Beatson Institute for Cancer Research, Glasgow, Scotland UK. In 2004 Neil returned to the pharmaceutical industry as Principal Scientist with the Advanced Science and Technology Laboratory at AstraZeneca where he pioneered early multiparametric high-content phenotypic screening approaches. In 2010 he once again made the career switch from industry to academia and took up the post of Principal Investigator of Drug Discovery at the University of Edinburgh where he leads a research group and is currently co-director of the Edinburgh Cancer Discovery Unit and the Edinburgh Phenotypic Assay Centre. Primary research interests include advancing High-content analysis, phenotypic screening, Reverse Phase Protein Array technology, drug combinations and cancer drug discovery. Neil is also Chief Scientific Officer of the Phenomics Discovery initiative, a public-private consortia to advance phenotypic screening technologies https://npsc.ac.uk/pdi and is a founding member of the European Cell Based Assay Interest group www.eucai.org and global RPPA society http://www.nmi.de/rppa2016/.
-
Drug screening in zebrafish larvae reveals inflammation-related modulators of secondary damage after spinal cord injury in mice
In:
Theranostics
DOI: https://doi.org/10.7150/thno.81332
Research output: Contribution to Journal › Article (E-pub ahead of print) -
Phenonaut; multiomics data integration for phenotypic space exploration
(2 pages)
In:
Bioinformatics, vol. 39
DOI: https://doi.org/10.1093/bioinformatics/btad143
Research output: Contribution to Journal › Article (Published) -
Macrophages promote anti-androgen resistance in prostate cancer bone disease
In:
Journal of Experimental Medicine, vol. 220
DOI: https://doi.org/10.1084/jem.20221007
Research output: Contribution to Journal › Article (E-pub ahead of print) -
YAP/TAZ activation predicts clinical outcomes in mesothelioma and is conserved in in vitro model of driver mutations
In:
Clinical and Translational Medicine, vol. 13, pp. e1190
DOI: https://doi.org/10.1002/ctm2.1190
Research output: Contribution to Journal › Article (Published) -
Glioblastoma and the search for non-hypothesis driven combination therapeutics in academia
In:
Frontiers in Oncology, vol. 12
DOI: https://doi.org/10.3389/fonc.2022.1075559
Research output: Contribution to Journal › Review article (E-pub ahead of print)